MEF2D and neoplasm: SIRT7 blockade can reduce the dual effect of PD-L1 on hepatocellular carcinoma cell proliferation and decrease anti-tumor immunity through MEF2D regulation, providing a basis for the development of combined SIRT7 inhibitors and anti-pd -(L)1 drugs for the treatment of hepatocellular carcinoma (40).